Veronica M. Kryshtal
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
The aim of the research: Improvement of the traditional complex treatment of voice-speaking professions during the COVID-2019 pandemic with functional dysphonia on the background of subclinical psycho-emotional disorders by appointment neurotransmitter drugs. Materials and methods: The study involved 49 people of voice-speech professions with functional disorders of the voice function of the hypotonic type, who were diagnosed with subclinical disorders of the psychoemotional state by questioning on the hospital anxiety and depression scale (HADS). Before and after treatment, voice disorders were diagnosed using perceptual evaluation of the GRBAS voice scale and video stroboscopy of the larynx. The impact of voice disorders on quality of life during the pandemic was assessed using the Voice COVID-19 (VC-19) questionnaire. All patients received standardized treatment, which consisted of the use of metabolic, stimulant drugs, physiotherapy and instillation of drugs into the larynx. In 26 patients of the main group (MG), in addition to treatment, a neurotransmitterotropic drug ("Beresh Magnesium plus B6") was prescribed. The comparison group (CG) consisted of 23 people who received traditional therapy. Descriptive statistics were used for statistical analysis of the effectiveness of treatment, comparison of the difference in quantitative indicators by the method of nonparametric statistics using the Mann-Whitney-U-test. Results: The use of the neurotransmitter correction agent "Beresh Magnesium plus B6" by the patients with MG contributed to the suppression of their susceptibility to anxiety, stress and, as a result of these processes, made it possible to obtain, in comparison with the control group, a significant improvement in such indicators of acoustic parameters as voice strength by 5.78%, integral stroboscopy index - 13.34% and improvement of the quality of life by 34.03%, which indicates the effectiveness of the use of magnesium compounds with vitamin B6 in the complex treatment of patients with hypotonic dysphonia against the background of subclinical psychoemotional disorders. Conclusions: Addit ional appointment of magnesium citrate and magnesium oxide compounds with vitamin B6, which has a modulating effect on neurotransmitters that affect depression and anxiety, to basic therapy for patients of main group, made it possible to obtain a significant improvement in the main perceptual and functional indicators of the voice and quality of life.
Year:
2022
Collaborators (2)
Iryna Sinaiko
Associate Professor
zaporizhzhia state medical and pharmaceutical university
Strohonova Tetiana
Associate Professor
zaporizhzhia state medical and pharmaceutical university
Make your next move.
Prepare your application
Review drafts before you send them.